- Researchers want to develop better ways to treat cancer. In this study, they will give people with cancer two drugs. These drugs have been used on their own to treat some blood cell cancers.
- To test the safety and efficacy of the drug combination of bortezomib and clofarabine.
- Adults age 18 and over with advanced cancer that has progressed after receiving standard treatment or that has no effective therapy.
General Director of Clínica Ruiz, Center of Hematology and Internal Medicine of Puebla; Director of research Division of Laboratorios Ruiz, within Clínica Ruiz; Professor of Hematology at the Autonomous Popular University of the State of Puebla
Hemant S. Murthy M.D., is a Hematology/Oncology physician, with specialty interest in BMT/CAR-T and acute leukemia practice. Dr. Murthy previously served as Assistant Professor of Medicine at the University of Florida College of Medicine in Gainesville, Florida. Prior to joining UF Health, Dr. Murthy was a transplant and cellular immunotherapy fellow at Moffitt Cancer Center.
The focus of Dr. Garcia's research is to develop novel proof-of-concept studies to gain insight on the underlying pathophysiology of acute leukemia and to identify biological predictors of response by partnering with Dana-Farber Cancer Institute laboratory investigators.
Dr. Traer completed a fellowship in hematology/oncology from Oregon Health & Science University. He received his M.D./Ph.D. from the University of Texas Southwestern Medical School and completed a residency in internal medicine at Oregon Health & Science University.
Dr. Litzow is Professor of Medicine in the Division of Hematology at Mayo Clinic in Rochester, Minnesota. He was the Director of the BMT Program at Mayo from 1992 to 2008 and continues to remain active in the BMT program. He was the Director of the Myeloid Disease Oriented Group in the Division of Hematology from 2002 to 2016. He was appointed chair of the Leukemia Committee of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) in September 2013 after having served as co-chair of the committee since 2001.